That is, because tau and amyloid-β PET are reliable and valid measures of underlying Alzheimer’s disease pathology, we can use PET as an indirect way to more accurately, and agnostically, assess connectivity differences that track with Alzheimer’s disease progression. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.